PRECISION1


Associated tags: Webcast, AADI, Medical imaging, Pharmaceutical industry, Neoplasm, CMO, Cancer, Pneumonitis, ORR, UPR, ID, Death, TSC2, LOS, Patient, Aadi, TSC1, Telephone, Safety, MD

Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations

Retrieved on: 
Thursday, December 14, 2023
Webcast, ID, Safety, Telephone, TSC1, Aadi, Patient, LOS, TSC2, Death, UPR, AADI, ORR, Pneumonitis, Cancer, CMO, Neoplasm, Pharmaceutical industry, Medical imaging, MD

LOS ANGELES, Dec. 14, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today reported results from a planned interim analysis on the first third of participants in the ongoing tumor-agnostic PRECISION1 trial evaluating nab-sirolimus in patients with TSC1 or TSC2 inactivating alterations. 

Key Points: 
  • "Our tumor agnostic PRECISION1 trial is designed to elucidate the impact of nab-sirolimus on cancers expressing inactivating alterations of TSC1 or TSC2, regardless of tumor type.
  • Nine different tumor types were enrolled in the TSC1 arm and 13 tumor types were enrolled in the TSC2 arm.
  • 80 patients are currently enrolled in the PRECISION1 trial, supporting the two-thirds interim analysis expected in the third quarter of 2024.
  • The Aadi management team is hosting a conference call and webcast today at 5:00 pm ET (2:00 pm PT) to discuss the interim results from the PRECISION1 trial.